Abstract 5553
Background
High inflammatory cytokine levels can lead to severe fatigue and alter the quality of life (QoL) of family caregivers (FCGs) of patients with head and neck cancer in palliative care (HNCPC). In addition, single nucleotide variants (SNVs) in cytokine genes, such as IL1B c-598T>C (rs16944), IL1R2 c.-2009G>A (rs4141134), IL6 c.-237G>C (rs1800795), and TREML2 c.430A>G (rs3747742), can influence individual differences in cytokine production. However, the roles of the referred SNVs on the QoL of FCGs are unknown. Thus, the aim of our study was to evaluate the influence of the referred SNVs in the QoL of FCGs of patients with HNCPC.
Methods
Genomic DNA of 100 FCGs of patients with HNCPC was analyzed by real-time PCR to identify the genotypes. QoL was measured with the abbreviated World Health Organization QoL questionnaire (WHOQOL-bref). The cut-off of the score was lower than 60 for worse QoL. Differences between groups were assessed by Fisher’s exact test, chi-square (bivariate analysis), and multiple linear regression.
Results
FCGs who carried IL6 GG (62.8% vs. 49.2%, odds ratio [OR]: 2.78, 95% confidence interval [CI]: 1.03-7.44, p = 0.04) and TREML2 AA (60.0% vs. 44.6%, OR: 2.68, 95% CI: 1.03-7.01, p = 0.04) had worse QoL for the overall QoL domain than non-carriers. The frequency of the genotype TREML2 AA was higher in FCGs with lower score for physical domain (61.0% vs. 42.4%, OR: 2.69, 95% CI: 1.05-6.87, p = 0.03). FCGs who carried IL1B TT genotype had worse QoL for the social domain than others (48.9% vs. 32.1%, OR: 3.49, 95% CI: 1.03-7.01, p = 0.01).
Conclusions
Genotypes of the IL1B, IL6, and TREML genes, associated with higher inflammatory levels, seem to influence the QoL of FCGs. We believe that our results can contribute to identify FCGs with worse QoL for physical, psychological, and social aspects and provide better and more specialized care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
FAPESP.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757 - Development of chimeric antigenic receptor (CAR) against VEGFR2 for solid tumor treatment
Presenter: Li-Shuang Ai
Session: Poster Display session 1
Resources:
Abstract
4156 - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells.
Presenter: Nunzia Matrone
Session: Poster Display session 1
Resources:
Abstract
2949 - EGFR-mediated PD-L1 upregulation in HER2+ breast cancer (BC) cell line models
Presenter: Nicola Gaynor
Session: Poster Display session 1
Resources:
Abstract
4270 - The impact of cortisol on immune cells and its effect on cancer-immune cells co-culture in a 3D spheroid of ovarian cancer
Presenter: Maysa Al-natsheh
Session: Poster Display session 1
Resources:
Abstract
1568 - Application of sonoporation to increase anticancer drug efficacy in 2D and 3D NSCLC cell cultures
Presenter: Vilma Petrikaite
Session: Poster Display session 1
Resources:
Abstract
5400 - Tr1-like cells in human peripheral blood are part of the T effector memory pool and are preferentially stimulated via CD55
Presenter: Iniobong Charles
Session: Poster Display session 1
Resources:
Abstract
5817 - Functional analysis of tumor infiltrating lymphocytes in triple negative breast cancer focusing on granzyme B
Presenter: Hitomi Kawaji
Session: Poster Display session 1
Resources:
Abstract
2287 - Aberrant glycolysis associates with inflammatory tumor microenvironment and promotes metastasis in triple-negative breast cancer
Presenter: Chengwei Lin
Session: Poster Display session 1
Resources:
Abstract
735 - Anti-cancer effects of differentiation-inducing factor-1 in triple negative breast cancer.
Presenter: Fumi Tetsuo
Session: Poster Display session 1
Resources:
Abstract
2105 - The Inhibitory Effect in Oral Squamous Cell Carcinoma Cells by Knocking down Matrix Metalloproteinase 9
Presenter: Xinyan Zhang
Session: Poster Display session 1
Resources:
Abstract